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Abstract 
The development and validation of an analytical method for the simultaneous 
analysis of five neutral lipids in Trypanosoma cruzi epimastigotes by GC-MS is 
presented in this study. The validated method meets all validation parameters for all 
components and the chromatographic conditions have been optimized during its 
development. This analytical method has demonstrated good selectivity, accuracy, 
within-day precision, recovery and linearity in each of the established ranges. In 
addition, detection and quantification limits for squalene, cholesterol, ergosterol and 
lanosterol have been improved and it is worth highlighting the fact that this is the first 
time that squalene-2,3-epoxide validation data have been reported. The new validated 
method has been applied to epimastigotes treated with compounds with in vitro anti-
T.cruzi activity. This new methodology is straightforward and constitutes a tool for 
screening possible sterol biosynthesis pathway inhibitors in Trypanosoma cruzi, one of 
the most studied targets in Chagas disease treatment. Therefore, it is an interesting and 
useful contribution to medicinal chemistry research. 
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1. Introduction 
The protozoan parasite Trypanosoma cruzi (T. cruzi) is the causative agent of Chagas 
disease (CD). CD has been classified as one of the 17 neglected tropical diseases by the 
World Health Organization (WHO) [1]. This parasitosis is endemic in 21 Latin 
American countries and as a result of migration flows, the number of cases has 
increased in non-endemic countries such as the USA, Canada, some European 
countries, and Japan and Australia [2, 3]. It is estimated that approximately 5.7 million 
people are infected by CD [4] and the disease causes approximately 7000 deaths 
annually, thereby becoming a serious public health problem [5]. The therapeutic arsenal 
against CD remains inadequate and insufficient. Currently, the only two drugs available 
for CD are nifurtimox and benznidazole. Both of them have issues related to toxicity 
  
and low efficacy in the chronic phase; neither one has been approved by the Food and 
Drug Administration (FDA) [6]. This scenario justifies the urgent need to develop safe 
and cost-effective therapeutic alternatives that can help fight against CD [1]. 
Advances in the study of the biochemistry and molecular biology of T. cruzi, and the 
complete sequencing of its genome have allowed identifying important molecular 
targets and specific metabolic pathways of T. cruzi that could be attacked by new drugs 
[7]. 
Sterols are a group of lipids classified as polycyclic steroids that have a structural 
function because they form part of the cell membrane. The presence of these sterols is 
essential for maintaining the viability and functionality of the plasma membrane in all 
eukaryotic cells. The different types of sterols are synthesized through a complex 
biochemical pathway called sterol biosynthesis pathway (SBP). This biochemical route 
is one of the most studied targets in the anti-T. cruzi drug discovery process [8]. 
Blocking SBP causes changes in the composition of the membrane [9], which causes 
defects in its ultra-structure [10]. These changes modify the physical properties and the 
activity of the membrane enzymes, leading to cell lysis [11]. 
Cholesterol is the main sterol in the mammalian system while in trypanosomatids, 
such as T. cruzi, the main sterols are ergosterol and 24-alkylsterols [12]. The de novo 
endogenous sterols biosynthesis in T. cruzi epimastigotes, unlike in mammals [11], 
would mainly take place in mitochondria [13] and glycosomes, and would reach the 
membrane through transporters [14]. This biochemical pathway (Figure 1) consists of 
two main stages, isoprenoids biosynthesis pathway (IBP) and SBP. The IBP starts with 
the condensation of two molecules of acetyl-CoA to form acetoacetyl-CoA and after 
several enzymatic reactions, squalene is obtained. The following stage corresponds to 
the SBP itself and involves the cyclization of squalene and its transformation into 
ergosterol. It is in this second phase where the differences between parasites and 
mammals can be found due to the presence of specific and characteristic enzymes [11, 
15]. 
 
Figure 1. Sterol biosynthesis pathway in T. cruzi epimastigotes 
  
 
Advances made in lipidomics have made it easier to study the lipid profile of 
trypanosomatids; it has been determined that C28 and C29 sterols are the most plentiful 
[16]. T. cruzi sterol composition varies according to the parasite stage during its life 
cycle. In epimastigote form, it has been observed that approximately 40% is consisted 
of C28 sterols such as ergosterol, 30% of C29 sterols, and a small percentages of C30 
sterols such as lanosterol and isoprenoids such as squalene and squalene epoxide [17, 
18]. In addition, it is known that approximately 10-50% ischolesterol derive from host 
or serum present in the culture medium [16, 17]. Despite this, T. cruzi needs to 
synthesize its endogenous sterols, essential for maintaining its viability and cell 
proliferation capacity in its different life stages [8]. 
The lipid composition and changes in the profile of T. cruzi epimastigotes have been 
studied by different research groups using various chromatographic methods, differing 
in the extraction, separation, detection, identification, quantification procedures and in 
the number of different types of lipids that can be evaluated simultaneously [13, 14, 18-
35]. Among these methodologies, simple methods with Thin‐Layer Chromatography 
(TLC) have been used, providing qualitative and semi-quantitative results [20-23]. In 
addition, methodologies with chromatography gas with mass detector (GC-MS) and 
FID detector have been used, allowing simultaneous determination of lanosterol, 
ergosterol and cholesterol, among other sterols [18-20]. Gerpe et al. presented a study 
using HPLC in which the detection and quantification limits determined for squalene 
were 0.6 and 2.1 µg/mL, respectively. With regard to ergosterol, a minimum value of 
2.7 µg/mL was reported [23]. Urbina’s group has spent many years researching the 
changes in the T. cruzi lipid profile after treatment with sterol biosynthesis pathway 
inhibitors (SBIs). In their different studies, using GC-MS with FID detector 
methodology, they reported minimum values of 1.9, 2.5, 1.8 and 6.1 % for squalene, 
lanosterol, ergosterol and cholesterol, respectively. These assays were carried out in 
SCAN conditions and lipid composition was determined for the library of compounds; 
values were expressed in mass percentage [13, 14, 24-31]. Overall, the described 
methodologies for the determination of the components of SBP in biological matrices 
are varied [32-34]. Nevertheless, some authors have considered GC-MS as one of the 
most efficient and accessible alternatives for lipid quantification in biological samples 
due to its high resolution and the existing economic and environmental advantages over 
other methods. Therefore, we decided to use this method in our study [35]. 
Different methods for the quantification of sterols have recently been validated in 
different biological matrices using GC-MS; however, no methods have been found that 
allow the simultaneous quantification of squalene, squalene-2,3-epoxide, lanosterol, 
ergosterol and cholesterol in T. cruzi epimastigotes. Furthermore, there is little 
information regarding the determination of squalene-2,3-epoxide in this biological 
matrix. Within this context, our work provides the development and validation of a new 
method capable of simultaneously analyzing five components of SBP by GC-MS in 
selected-ion monitoring conditions (SIM) in this biological matrix. The development 
and validation of this method is a useful analytical tool and an important contribution to 
  
the field of medicinal chemistry as a possible method for identifying SBIs in the drug 
discovery process for the treatment of CD. 
In order to study the applicability of the new validated method, some compounds 
with interesting in vitro activity against T. cruzi were assessed to determine their 
possible inhibitory effect against SBP. 
 
2. Materials and methods 
 
2.1. Chemicals 
The sterols reference standards squalene ([111-02-4], ≥ 98%, [Wisconsin, US]), 
2,3-oxidosqualene ([7200-26-2], ≥ 92%, [Bengalore, India]), cholesterol ([57-88-5], ≥ 
99%, [Missouri, US]), ergosterol ([57-87-4], ≥ 95%, [Buchs, Switzerland]), and 
lanosterol ([79-63-0], ≥ 93%, [Missouri, US]) were supplied by Sigma-Aldrich. 
Methanol was purchased from AppliChem Panreac (Barcelona, Spain), hexane was 
obtained from Merck KGaA (Germany) and chloroform was purchased from Quimipur 
(Madrid, Spain). Sodium chloride and sodium phosphate for buffer solution were 
obtained from Panreac (Barcelona, Spain). 
 
2.2. Biological material 
T. cruzi epimastigote Tulahuen 2 and Y strains were obtained from the Grupo de 
Química Medicinal-Laboratorio de Química Orgánica, Facultad de Ciencias 
Universidad de la República de Uruguay. 
 
2.3. Standard solutions preparation 
An individual stock solution was prepared in hexane for each concentration for 
each reference standard, correcting the stock concentration based on the purity data 
obtained; the solutions were stored a -20ºC. Working solutions were freshly prepared 
prior to each assay by diluting each reference standard in the same solvent. 
 
2.4. Sample preparation method for membrane sterols 
Epimastigote culture from Tulahuen 2 (DTU Tc VI) and Y (DTU Tc II) strains of 
T. cruzi were used to obtain membrane sterols. A negative control (NC) was assessed 
with epimastigote culture without compound, and Terbinafine (Tbf) was used as 
positive control at a dose of IC50= 44.7 µM. The selected compounds (IC50 
concentration) were incubated with epimastigote culture at 10 million per mL for 72 h at 
28 ºC. After incubation time, the epimastigote culture was centrifuged at 3000 rpm for 
10 min. The obtained supernatant was discarded. The pellet was re-suspended in 6 mL 
of 0.05 M sodium phosphate buffer solution pH 7.4 and then centrifuged again at 3000 
rpm for 10 min (Step A). The supernatant was discarded and the pellet was re-
suspended in 5 mL of chloroform:methanol mixture 2:1. The suspension was then kept 
for 12 h at 4 ºC. Next, 5 mL of saturated NaCl solution was added and the mixture was 
extracted with 3 mL of chloroform and with 3 mL of hexane, taking special care to 
avoid collecting any aqueous phase (Step B) [22]. The extracted volume was evaporated 
with nitrogen gas. The sample was re-dissolved in 600 µL of hexane and then injected 
  
into the GC-MS equipment at the development conditions (Step C).  OJO (arriba en 
amarillo): “from” versus “of”. ¿El cultivo esta HECHO DE (= “of”) esas dos cepas o SE 
SACA el cultivo DESDE esas 2 cepas, como en “provenir de” (= from). Yo CREO que 
debe ser “of”, no te parece? Ya me dirás. Se cultivan epimastigotes de esas dos cepas 
por lo tanto yo creo que from 
 
2.5. GC-MS analysis and conditions 
Chromatographic separation was performed on an Agilent 6890 gas chromatograph 
(GC) coupled to a 5973 quadrupole mass spectrometer (MS) from Agilent 
Technologies, USA. The injector was programmed at 250 ºC and a splitless injection 
mode was used. Aliquots of 2 µL of the sample dissolved in hexane were injected into 
GC-MS. Separation of the sterols was carried out using HP-5-MS 30 m x 0.25 mm i.d. x 
0.5 µm column (Agilent Technologies, USA). The carrier gas was helium, at a constant 
flow rate of 1 mL min-1. The GC oven temperature started at 150 ºC, and then was 
ramped to 250ºC at 40 ºC min-1. Next, the temperature was raised to 300 ºC at 5 ºC min-
1 and held there for 3.5 min. The source temperature was fixed at 280 ºC and MS 
worked in electron impact mode (EI, 70 eV). In order to avoid overloading the GC-MS 
with hexane, a solvent delay of 4 min was implemented. The mass spectra were 
acquired over the mass-to-charge (m/z) range of 50-600. The SIM conditions for the 
neutral lipids were determined after the identification of the most abundant and 
characteristic ions in SCAN conditions. Integration was performed with Chemstation 
integrator. 
 
2.6. Method validation parameters 
The validation was based on the criteria established by current regulations for 
bioanalytical methods. Selectivity, stability, limit of detection (LOD), limit of 
quantification (LOQ), range, linearity, precision, accuracy and recovery were studied 
[36, 37]. 
 
2.7. Calibration curve 
Calibration samples were prepared by spiking matrix, previously prepared with 
extraction dissolvent in step B. First, five different individual concentrated solutions 
were prepared: squalene (850 µg/mL), squalene-2,3-epoxide (100 µg/mL), cholesterol 
(500 µg/mL), lanosterol (200 µg/mL) and ergosterol (200 µg/mL). Next, the 
corresponding volume was measured to prepare a stock solution containing the mixture 
of these 5 components at 101, 48, 48, 32, 16 µg/mL, respectively. Serial dilutions were 
made from this stock solution in order to obtain the solution containing the mixture for 
each concentration level. 
 
2.8. Application of the GC-MS method to real samples 
The new validated GC-MS method was applied to obtained extracts (step C) from 
treated epimastigotes with reference drug Tbf (positive control) and with our anti-T. 
cruzi compounds; untreated epimastigotes were used as negative control (NC). The 
quantitative determination was performed following the previously explained 
  
experimental procedure. The calibration curves were prepared in triplicate daily. The 
concentration of lipids after the treatment with the compounds (S) was determined in 
µg/mL. With these obtained values, we calculated the accumulation percentage (A%) or 
depletion percentage (D%) of lipid using the following equation: 
% = [(S*100/Total lipid concentration obtained from the NC)-100]. 
A positive result indicates accumulation (A) and a negative result indicates depletion 
(D). 
3. Results and discussion 
 
3.1.Optimization of GC-MS analysis and conditions 
In order to optimize the chromatographic separation of the five neutral lipids, the 
abundances of fragmented ions obtained and the different temperature gradients were 
assessed. As a result, the methodology described in section 2.5 was developed. Table 1 
shows monitoring ions and retention times for each lipid. The elution order was: 
squalene, squalene-2,3-epoxide, cholesterol, ergosterol and lanosterol (Figure 1). 
 
Table 1. GC-MS SIM conditions for the studied sterols. 
Sterol RT (min) SIM (m/z) 
Squalene 9.03 81, 137*, 341,  410 
Squalene-2,3-epoxide 10.14 69, 81, 121, 135, 426 
Cholesterol 12.09 275, 301, 353, 368, 386 
Ergosterol 13.01 337, 363, 396 
Lanosterol 14.59 393, 411, 426 
RT: Retention time, (Characteristics ions). 
*Extracted ion (137) was used for quantification of squalene.  
 
3.2.Validation method 
The selectivity of the method allowed an adequate separation between squalene, 
squalene-2,3-epoxide, cholesterol, ergosterol and lanosterol. As shown in Figure 2, no 
interference peaks were detected in the retention times of the neutral lipids that were 
analyzed. Moreover, no interaction was observed among the sterols nor between sterols 
and the matrix. 
  
 
Figure 2. Chromatogram obtained at the optimized conditions of the validated 
method. 
 
In this study, stability of the sterol samples was evaluated at two different storage 
temperature conditions. The sample was considered to be stable when it presented a 
recovery percentage over 90%. First, stability was assessed at room temperature every 
12 h in a 60-h period. It was also measured after 24 h of freezing at -20ºC. The stability 
study at room temperature revealed that the 5 studied sterols were stable up to 36 h 
except for squalene-2,3-epoxide, which remained stable for 24 h (Figure 3 and 
supplementary data). Thus; the stability of the 5 neutral lipids at room temperature for 
24 h is guaranteed. 
 
Figure 3. Stability study at room temperature. Samples were evaluated in triplicate and 
have shown RSD<15%. 
 
Linearity was determined using the three spiking samples at a minimum of 5 
concentration levels each, within the ranges shown in Table 2. The average obtained 
from the three spiking samples at each level of concentration met the established RSD 
in all concentrations. The range of all lipids was set considering LOQ as the lower limit, 
and 12 times LOQ as the upper limit for squalene-2,3-epoxide, 30 times LOQ for 
ergosterol and 100 times LOQ for squalene, cholesterol and lanosterol. While squalene-
  
2,3-epoxide displayed a unique linear range, the other lipids exhibited two linear ranges 
(Table 2). The obtained linear regression for each lipid reported good linear 
determination coefficient (R2>0.98). Furthermore, it has been confirmed that the 
intercept is not statistically different from the zero value and that the slope is 
significantly different from the zero value with a 95% confidence interval. As for 
residuals analysis, it was observed that their behavior is random and does not reflect a 
definite trend. 
 
LOD and LOQ were determined in the three spiking samples, at their respective 
concentration levels, according to AEFI by the signal-to-noise (SN) method. LOQ for 
squalene, squalene-2,3-epoxide, cholesterol and lanosterol was in the range of 0.13-3.10 
µg/mL. In addition, obtained concentrations met the accuracy criteria (%error<20%), 
precision (RSD<15%), and recovery percentages (80-120%), and their values were 
higher than 10 times the SN. With respect to the LOD of the five lipids, they were 
within a concentration range of 0.05-1.86 µg/mL, and these concentrations exhibited 
values greater than 3 times the SN (Table 2). 
 
To determine the accuracy and precision (within-day and between-days), three 
spiking samples corresponding to high, medium and low concentrations within the 
ranges for every neutral lipid were evaluated. At precision within-day analysis, all lipid 
RSD values were in the range of 1.94-14.99%. The values obtained satisfied the 
established parameters (RSD≤15%) at the three levels tested. 
 
Precision between-days were measured on three different days. Squalene (range: 
6.54-84.15 µg/mL), squalene-2,3-epoxide (range: 3.10-39.89 µg/mL) and ergosterol 
(2.09 and 3.49 µg/mL) had a RSD≤15%. Meanwhile, the other lipid concentrations and 
the lowest concentration range of squalene exhibited RSD>15%. Taking into account 
that all lipids were precise within-day, but at several concentrations levels did not 
present an acceptable precision between-days, a daily calibration curve was prepared to 
evaluate the samples. 
 
With regard to accuracy, it was proven that the method met the requirement set for 
this parameter. The method gave values of percentage error in a range of 3.35-19.28% 
(%error allowed ± 20%) for the lower concentrations and a range of 0.36-14.65% 
(%permissible error ± 15%) for the rest of the concentrations (Table 2). 
 
  
Table 2. Validation method data: Linearity, range, precision and detection and quantification limits. 
Sterols RT (min) 
SIM 
(m/z) 
Range 
(µg/mL) 
Linearity 
y = bx ± a 
Determination 
coefficient (R2) 
Fortification 
level 
(µg/mL) 
Mean 
 
Accuracy Precision (%RSD) 
LOD 
(µg/mL) 
LOQ 
(µg/mL) 
(%RSD) (% Error) 
Within-
day  
Between-
days  
Squalene  9.03 
81,  
137*, 
341, 
 410 
0.85 – 
6.54 
y = 180880.13x -
47122.95 0.9884 
0.85 1.01 19.28 1.94 > 15 
0.31 0.85/ 1.94 
2.36 2.02 14.11 14.89 > 15 
6.54 5.59 1.96 2.04 14.97 
6.54 – 
84.15 
y = 189769.93x + 
99777.38 0.9958 
6.54 6.67 14.65 2.04 14.97 
30.29 33.34 10.07 5.17 10.85 
84.15 83.42 0.87 2.48 12.18 
Squalene-
2,3-epoxide 10.14 
69, 81, 
121, 
135, 426 
3.10 – 
39.89 
y = 1152017.41x -
850168.65 0.9977 
3.10 2.99 3.60 3.13 13.31 
1.86 3.10/ 3.13 8.62 8.03 6.80 4.96 12.59 
39.89 39.66 0.57 3.54 14.98 
Cholesterol  12.09 
275, 
301, 
353, 
368,  
386 
0.40-
1.87 
y = 203170.23x -
21519.56 0.9960 
0.40 0.42 3.35 6.85 > 15 
0.24 0.40/ 6.85 
1.12 1.07 2.15 14.90 > 15 
1.87 1.89 1.16 6.99 > 15 
1.87-
39.98 
y = 429645.90x -
326847.43 0.9990 
1.87 1.60 14.07 6.99 > 15 
8.64 8.12 5.97 3.80 > 15 
39.98 39.84 0.35 4.02 > 15 
Ergosterol  13.01 
337, 
363,  
396 
0.75-
3.49 
y = 331790.17x -
222286.57 0.9829 
0.75 0.90 19.17 13.38 > 15 
0.16 0.75/ 13.38 
2.09 2.07 1.07 7.97 13.50 
3.49 3.53 1.17 14.99 11.38 
3.49-
26.94 
y = 309500.10x -
85786.37 0.9967 
3.49 3.35 4.13 14.99 11.38 
9.70 10.42 7.43 14.66 > 15 
26.94 26.79 0.55 14.20 > 15 
Lanosterol  14.59 
393, 
411,  
426 
0.13-
0.62 
y = 140037.54x   -
9134.59 0.9904 
0.13 0.15 10.67 5.63 > 15 
0.05 
0.13/ 
5.63 
 
0.37 0.35 6.14 14.61 > 15 
0.62 0.63 1.90 9.26 > 15 
1.03-
13.30 
y = 230785.03x -
24253.01 0.9991 
1.03 0.95 8.55 7.51 > 15 
4.79 4.99 4.29 3.07 > 15 
13.30 13.25 0.36 5.17 > 15 
RT: Retention time, SIM: Selected ion monitoring (Characteristics ions). *Extracted ion (137) was used for quantification of squalene.  
  
It is noteworthy that the developed method has improved LOD and LOQ for 
squalene, cholesterol, ergosterol and lanosterol in this biological matrix with respect to 
the method described in literature up to now [23]. The validated method has allowed the 
simultaneous quantification of squalene, cholesterol, ergosterol and lanosterol. 
Therefore, this method is proposed as a fast screening method for the identification of 
SBIs with activity against T. cruzi. 
 
3.3. Application of the method to real samples 
 A possible target for the discovery of antichagasic drugs is the SBP. The inhibition 
of any of the enzymes involved in this pathway would cause accumulation of its 
substrate and the depletion of the corresponding product which could cause the death of 
the parasite.  
 The inhibitory capacity of anti-T. cruzi compounds on some enzymatic reactions of 
the SBP was evaluated by the GC-MS method in Tulahuen 2 and Y strains. Squalene, 
lanosterol and ergosterol were quantitatively determined in real samples. Although 
squalene-2,3-epoxide has been detected, it has not been possible to quantify its 
concentration because it was below its LOQ 
 Table 3 shows the results obtained by the new validated GC-MS method in 
samples of untreated Tulahuen 2 strain epimastigotes (NC), those treated with the 
reference drug Tbf and those treated with 8 compounds with in vitro anti-T. cruzi 
activity. Tbf showed squalene and lanosterol accumulation and ergosterol depletion as 
expected because Tbf is a known SBI [38]. These results seem to corroborate the inhibitory 
activity of terbinafine on the enzymes squalene-2,3-epoxidase and CYP51 described in the 
literature [8, 39]. 
 Five of the eight compounds (1, 2, 4, 5 and 7) showed ergosterol depletion. 
Compounds 4 and 5 stood out for presenting the highest percentages of depletion, 
especially compound 4 because it showed the same depletion percentage as Tbf. Taking 
into account the SBP (Figure 3), these results appear to indicate that compounds 4 and 
5 could be causing an inhibitory effect on Lanosterol 14-demethylase (CYP51) because 
a marked accumulation of lanosterol is observed in T. cruzi Tulahuen 2 strain 
epimastigotes. 
 
Table 3. Squalene, Lanosterol and Ergosterol quantification in Tulahuen 2 strain  
Code 
Squalene Lanosterol Ergosterol 
µg/mL A% D% µg/mL A% D% µg/mL A% D% 
NC 1.15   0.13   1.30   
Tbf 1.28 11.30 - 0.20 53.85 - 0.90 - -30.77 
1 1.17 1.74 - 0.42 223.08 - 1.23 - -5.38 
2 1.27 10.43 - 0.21 65.54 - 1.21 - -6.92 
3 1.21 5.22 - 0.35 169.23 - 1.33 2.31 - 
4 1.16 0.87 - 0.21 61.54 - 0.90 - -30.77 
5 1.09 - -5.22 0.29 123.08 - 1.04 - -20.00 
6 1.32 14.78 - 0.46 253.85 - 1.81 39.23 - 
7 1.57 36.52 - 0.17 30.77 - 1.29 - -0.77 
  
 
NC: Negative control, Tbf: Terbinafine, %A: accumulation percentage; %D: depletion percentage. 
 
 Table 4 presents the results obtained in the Y strain T. cruzi epimastigotes. In this 
strain, Tbf showed the same behavior as in the Tulahuen 2 strain. Table 4 shows that all 
compounds exhibited ergosterol depletion. Compounds 1, 3, 4, 5, 6, 7 and 8 showed the 
greatest ergosterol depletion percentages, similar or even higher than those of Tbf. 
Compounds 1 and 4 produced squalene and lanosterol accumulation with consequent 
depletion of ergosterol. This behavior may suggest a Squalene-2,3-epoxidase and 
CYP51 inhibitory activity, enzymes involved in the squalene and lanosterol 
transformation. Compounds 3 and 8 showed squalene accumulation causing lanosterol 
and ergosterol depletion. This appears to indicate a Squalene-2,3-epoxidase inhibition, 
enzyme involved in the squalene transformation. Compounds 5 and 6 showed lanosterol 
accumulation, so they could be acting as possible CYP51 inhibitors. Compound 7 
showed ergosterol depletion without squalene or lanosterol accumulation, suggesting a 
possible inhibition of prior enzymes to the squalene biosynthesis. 
 
Table 4. Squalene, Lanosterol and Ergosterol quantification in Y strain.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NC: Negative control, Tbf: Terbinafine, %A: accumulation percentage; %D: depletion percentage. 
 
 The Y strain SBP seems to be more sensitive to the tested compounds than the 
Tulahuen 2 strain. This could be explained by the genetic differences between both 
strains [40]. 
 
4. Conclusions 
In this paper we have reported a validated methodology for the quantification of 
neutral lipids in T. cruzi epimatigotes using GC-MS in SIM conditions. The new 
method achieved an important improvement in LOD and LOQ for squalene (0.31 and 
0.85 µg/mL), squalene-2,3-epoxide (1.86 and 3.10 µg/mL), cholesterol (0.24 and 0.40 
µg/mL), ergosterol (0.16 and 0.75 µg/mL) and lanosterol (0.05 and 0.13 µg/mL), 
respectively. In addition, the method is linear in two ranges for all the neutral lipids 
studied except for squalene-2,3-epoxide which has a single linear range, thereby 
8 1.26 9.57 - 0.13 - - 1.43 10.00 - 
Code 
Squalene Lanosterol Ergosterol 
µg/mL A% D%  µg/mL A%  D%  µg/mL A%  D%  
NC 1.03   0.24   1.82   
Tbf 1.29 25.24 - 0.36 50.00 - 1.31 - -28.02 
1 1.31 27.18 - 0.32 33.33 - 1.10 - -39.56 
2 1.21 17.48 - 0.23 - -4.17 1.70 - -6.59 
3 1.13 9.71 - 0.24 - - 1.01 - -44.51 
4 1.35 31.07 - 0.52 116.67 - 1.21 - -33.52 
5 1.02 - -0.97 0.37 54.17 - 1.01 - -44.51 
6 0.96 - -6.80 0.37 54.17 - 1.04 - -42.86 
7 0.97 - -5.83 0.20 - -16.67 0.97 - -46.70 
8 1.26 22.33 - 0.13 - -45.83 1.41 - -22.53 
  
enhancing the results published so far. The novelty of this method is that it provides a 
linear range for the quantification of squalene-2,3-epoxide. However, the squalene-2,3-
epoxide concentration was below its LOQ in real samples. Hence, it is suggested that 
the concentration of epimastigotes in the culture medium should be increased in order to 
obtain quantifiable values. The method has been proven to be selective within-day, 
precise, accurate and with good recovery values. The innovation of this research is its 
applicability within the field of medicinal chemistry because simultaneous 
quantification of 4 neutral lipids essential for the viability of T. cruzi has been achieved.  
 
This new method facilitates the identification of possible SBIs, being a rapid 
screening method for determining the possible mechanism of action of active 
compounds against the parasite. Therefore, its suitability as a screening methodology in 
the identification of possible SBIs in the discovery process for new drugs for treating 
CD has been demonstrated. 
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